SOPHiA GENETICS Announces Impressive First Quarter 2026 Financial Results

SOPHiA GENETICS: First Quarter 2026 Financial Results

SOPHiA GENETICS, traded on Nasdaq under the symbol SOPH, has reported robust financial results for the first quarter of 2026, marking a positive trajectory in its operations within the Ai-driven precision medicine domain. For the quarter that ended on March 31, 2026, the company revealed a revenue of $21.7 million, a compelling 22% increase from the same quarter in the previous year.

Financial Overview

The gross margin for this quarter stood at 68.0% based on reported figures, while it reached 75.4% when adjusted, showing a slight decrease compared to last year's gross margins of 68.7% and 75.7% respectively. Despite these positive indicators, the company faced an IFRS net loss of $19.3 million, reflecting an 11% increase year-over-year. Adjusted EBITDA loss was reported at $9.2 million, which represents a 3% improvement over the previous year.

CEO Jurgi Camblong noted the impressive revenue growth and the notable delivery of 108,000 genomic analyses using the SOPHiA DDM™ platform, highlighting a growing demand for their services particularly in U.S. hospitals and laboratories. The interest in promising new applications such as Liquid Biopsy and Enhanced Exomes paved the way for an optimistic outlook ahead.

Expanded Customer Engagement

The company has made significant strides in customer engagement, achieving a 16% growth in analysis volume. Notably, the U.S. market exhibited a remarkable 28% growth in analysis volume, while the Asia-Pacific region saw a 31% increase. The revenue from Europe and the Middle East rose by 30%. SOPHiA GENETICS also witnessed an increase in the Net Dollar Retention rate, which climbed to 117% in Q1 2026, up from 103% a year ago.

Furthermore, they secured three significant contracts in EMEA, each exceeding $1 million per annum. The total count of core genomics customers reached 537, up from 490 in the previous year, indicating solid growth in their customer base.

New Partnerships and Business Expansion

SOPHiA GENETICS also made headway in acquiring new customers, signing 18 additional core genomic clients in Q1 2026, which are projected to contribute to revenue within the next year. Renowned global healthcare institutions such as CHU Bordeaux's Hospital and Maastricht UMC are among the new affiliates choosing SOPHiA’s advanced solutions for their genomic analyses.

Strategic Focus on BioPharma

With regard to BioPharma collaborations, the company displayed encouraging revenue growth in Q1, thanks to new projects that have started generating revenue. The company continues to explore partnerships that will aid in evidence generation, commercialization, and the development of future companion diagnostic offerings.

Commitment to Operational Excellence

SOPHiA GENETICS maintained a commendable adjusted gross margin in Q1 2026, optimizing operational costs through effective use of their cloud-native platform, which suggests a commitment to sustained operational excellence. In line with this strategy, SOPHiA has initiated targeted cost reductions and emphasized enhancing productivity while maintaining investments in key growth areas.

As for projections for the full year 2026, SOPHiA GENETICS expects revenue to range between $92 million and $94 million, equating to a year-over-year growth of approximately 20% to 22%. Their anticipated adjusted EBITDA loss is estimated between $29 million and $32 million, a decrease from last year’s adjusted loss of $41.5 million.

In conclusion, SOPHiA GENETICS' first quarter results demonstrate a solid start to 2026, showcasing strong revenue growth, expanding customer engagement, and a focused approach to operational excellence, positioning the company for continued success in the evolving landscape of precision medicine. Investors and stakeholders alike can look forward to further developments during the year as they push forward with innovative solutions in healthcare.